Approval · Notice of Compliance 38353 · 2026
ADVAIR: Notice of Compliance 38353
Issued September 24, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38353
- Date
- September 24, 2026
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Replacement of a primary container closure system
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ADVAIR | Not yet assigned | — |
Medicinal ingredients
- FLUTICASONE PROPIONATE 125 MCG per ACT
- SALMETEROL XINAFOATE 25 MCG per ACT
- FLUTICASONE PROPIONATE 250 MCG per ACT